ArticleCardiology and therapy2026
Adverse Remodeling and Prognostic Significance of the Systemic Right Ventricle Across Congenital Heart Disease Subtypes.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with congenitally corrected transposition of the great arteries (ccTGA), atrial-corrected transposition (acTGA), and right-ventricular-dominant univentricular heart (UVH) are predisposed to systemic right ventricular dysfunction (sRVd). However, lesion-specific differences in the incidence and timing of adverse outcomes remain unclear. This study aimed to compare the incidence of sRVd, tricuspid regurgitation (TR), and mortality across sRV lesions, and to identify their predictors.
methodsRetrospective 207 patients with an sRV diagnosed between 1975 and 2023 were categorized into acTGA (n = 53), UVH post-Fontan (n = 75), and ccTGA (n = 79). Incidence, survival analyses and Cox proportional hazards models were assessed for sRVd, TR and mortality.
resultsThe overall incidence of sRVd was 33.3% at a median age of 26.9 years. At the latest follow-up, sRVd was predominant in the acTGA group (37.7%), compared with UVH (16%) and ccTGA (16.5%). Remarkably, freedom of sRVd at 20 and 40 years were 65.9%, 13% in acTGA group; 30.5%, 5.8% in the UVH group and 43.5%, 26.6% in the ccTGA group, respectively (p < 0.001). Independent predictors included Ebsteinoid TV, pulmonary atresia, acTGA, and UVH. The 20- and 40-years survival was 62.3%, 14.7% (acTGA), 35.2%, 1.5% (UVH), and 46.8%, 22.7% (ccTGA) (p < 0.001). Mortality was associated with PA and NYHA functional class III-IV. Moderate-to-severe TR occurred in one-third of patients. Notably, TR interventions were predominant in ccTGA (p = 0.009).
conclusionsSRV lesions exhibit distinct clinical phenotypes: acTGA carries the highest overall prevalence of dysfunction, UVH demonstrates the earliest onset, and ccTGA encounters the highest frequency of TR interventions. Despite these differing deterioration patterns, patients with biventricular configurations confer a survival advantage over single-ventricle physiology. These results underscore the importance of anatomy-specific monitoring and timely functional assessment, while also accounting for differences in age and follow-up duration when evaluating long-term outcomes. Graphical abstract available for this article. CLINICAL TRIAL REGISTRY NUMBER: TCTR20250107006.
Indexed as
Identifiers
42758415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.